Skip to main content

Table 1 EBMT criteria for SOS/VOD in adults and children

From: Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Adults [38]

Children [39]

Classical (first 21 days after HSCT)

Bilirubin ≥ 2 mg/dL and 2 of the following criteria must be present:

• Painful hepatomegaly

• Weight gain > 5%

• Ascites

Late onset (> 21 days after HSCT)

Classical VOD/SOS beyond day 21

OR

Histologically proven SOS/VOD

OR

 ≥ 2 of the following criteria must be present:

• Bilirubin ≥ 2 mg/dL (or 34 μmol/L)

• Painful hepatomegaly

• Weight gain > 5%

• Ascites

AND hemodynamical and/or ultrasound evidence of SOS/VOD

No limitation for time of onset of SOS/VOD

The presence of ≥ 2 of the following:a

• Unexplained consumptive and transfusion-refractory thrombocytopeniab

• Otherwise unexplained weight gain on 3 consecutive days despite the use of diuretics or a weight gain > 5% above baseline value

• Hepatomegalyc (best if confirmed by imaging) above baseline value

• Ascitesc (best if confirmed by imaging) above baseline value

• Rising bilirubin from a baseline value on 3 consecutive days or bilirubin ≥ 2 mg/dL within 72 h

  1. EBMT European Society for Blood and Marrow Transplantation; HSCT hematopoietic stem cell transplantation; SOS/VOD sinusoidal obstruction syndrome/veno-occlusive disease
  2. aWith the exclusion of other potential differential diagnoses
  3. b≥ 1 weight-adjusted platelet substitution/day to maintain institutional transfusion guidelines
  4. cSuggested: imaging immediately before HSCT to determine baseline value for both hepatomegaly and ascites